Assessing patients' information needs regarding drug-drug interactions

Journal of the American Pharmacists Association

Volumn 53, Issue 1, 2013, Pages 39-45

  Mutebi, Alex ^a   Warholak, Terri L ^a   Hines, Lisa E ^a   Plummer, Rose ^b   Malone, Daniel C ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b MediGuard   (United States)

Author keywords

Drug information; Drug interactions; Patient preferences

Indexed keywords

NON PRESCRIPTION DRUG; PRESCRIPTION DRUG;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CAUCASIAN; COMORBIDITY; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; DRUG INFORMATION; DRUG INTERACTION; DRUG MARKETING; DRUG MONITORING; FEMALE; FOOD DRUG INTERACTION; HEALTH SURVEY; HUMAN; INFORMATION SERVICE; MAJOR CLINICAL STUDY; MALE; NEEDS ASSESSMENT; PATIENT EDUCATION; PENSIONER; QUESTIONNAIRE; RISK REDUCTION; SEX DIFFERENCE;

EID: 84890024702     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2013.12038     Document Type: Article

References (25)

1. Braverman SE, Howard RS, Bryant PR, Belandres PV. Potential drug interactions in a physical medicine and rehabilitation clinic. Am J Phys Med Rehabil. 1996;75(1):44-9.
2. Hines LE, Murphy JE, Grizzle AJ, Malone DC. Critical issues associated with drug-drug interactions: highlights of a multistakeholder conference. Am J Health Syst Pharm. 2011;68(10):941-6.
3. Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009;12(3):266-72.
4. Hamilton RA, Briceland LL, Andritz MH. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy. 1998;18(5):1112-20.
5. Institute of Medicine. Preventing medication errors: quality chasm series. Washington, DC: National Academies Press; 2007.
6. Berlin A, Sorani M, Sim I. A taxonomic description of computer-based clinical decision support systems. J Biomed Inform. 2006;39(6):656-67.
7. Tamblyn R, Huang A, Perreault R, et al. The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care. CMAJ. 2003;169(6):549-56.
8. Chaudhry B, Wang J, Wu S, et al. Systematic review: impact of health information technology on quality, efficiency, and costs of medical care. Ann Intern Med. 2006;144(10):742-52.
9. Trewin VF, Veitch GB. Patient sources of drug information and attitudes to their provision: a corticosteroid model. Pharm World Sci. 2003;25(5):191-6.
10. Alkhawajah AM, Eferakeya AE. The role of pharmacists in patients' education on medication. Public Health. 1992;106(3):231-7.
11. American Society of Health-System Pharmacists. Top patient concerns 2002 omnibus survey results. www.ashp.org/s-ashp/docs/files/PR-ResearchReport.pdf. Accessed November 23, 2011.
12. Indermitte J, Reber D, Beutler M, et al. Prevalence and patient awareness of selected potential drug interactions with self-medication. J Clin Pharm Ther. 2007;32(2):149-59.
13. Ko Y, Malone DC, Skrepnek GH, et al. Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Saf. 2008;31(6):525-36.
14. Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care. 2002;40(12):1161-71.
15. Weideman RA, Bernstein IH, McKinney WP. Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm. 1999;56(15):1524-9.
16. Cohen MR. Medication errors: causes, prevention, and risk management. Sudbury, MA: Jones & Bartlett; 2000.
17. MediGuard. Homepage. www.mediguard.org. Accessed November 23, 2011.
18. Cascade E, Bharmal M, Rosen S, Plummer RC. Patient preferences for adherence enhancing tools. Journal of Communication in Healthcare. 2010;3(3-4):266-78.
19. Braun V, Clark V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006;3(2):77-101.
20. Ryan GW, Bernard HR. Techniques to identify themes. Field Methods. 2003;15(1) 85-109.
21. Frosch DL, Grande D, Tarn DM, Kravitz RL. A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising. Am J Public Health. 2010;100(1):24-32.
22. Mintzes B, Barer ML, Kravitz RL, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ. 2003;169(5):405-12.
23. Brass EP. Consumer behavior in the setting of over-the-counter statin availability: lessons from the consumer use study of OTC Mevacor. Am J Cardiol. 2004;94(9A):22-9F.
24. Malone DC, Abarca J, Hansten PD, et al. Identification of serious drugdrug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc. 2004;44(2):142-51.
25. Bertoli R, Bissig M, Caronzolo D, et al. Assessment of potential drug-drug interactions at hospital discharge. Swiss Med Wkly. 2010;140:w13043.